

ALLG Trial Number:	CLL6
Trial Name:	An Australasian, Phase III, Multicentre, Randomised trial comparing lenalidomide consolidation vs no consolidation in patients with Chronic Lymphocytic Leukemia and residual disease following induction chemotherapy (RESIDUUM)
Lay Summary:	For some people with chronic lymphocytic leukaemia (CLL), treatment works very well and there are no signs of cancer after their first course of chemotherapy. In other patients, this 'induction' chemotherapy doesn't kill all of the leukaemia cells in the body. These patients don't tend to do as well because the leukaemia eventually comes back. Lenalidomide is a drug that is known to kill CLL cells which are resistant to induction chemotherapy. This study looks at whether patients with resistant CLL do better if they take lenalidomide after induction chemotherapy compared to those who do not take lenalidomide.
Participating Hospitals:	1. Austin Health / 2. Bendigo / 3. Border Medical Oncology / 4. Cairns Base / 5. Calvary Mater Newcastle / 6. Canberra / 7. Concord / 8. Gosford / 9. Northern / 10. Peter MacCallum / 11. Princess Alexandra / 12. Royal Hobart / 13. Royal Melbourne / 14. Royal North Shore / 15. Royal Prince Alfred / 16. Sir Charles Gairdner / 17. St Vincent's Melbourne / 18. Townsville / 19. Tweed / 20. Western / 21. Westmead / 22. Wollongong
Target Accrual (International):	320 patients registered, 192 patients randomised
Target Accrual (ALLG):	160 patients registered, 91 patients randomised
Expected Final Accrual Date:	January 2016